Sign In
Buy MGTX
$12.52
+0.310 (+2.54%)
At Close: Jul 21, 2026
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
08:00am, Tuesday, 13'th May 2025
- Announced strategic collaboration with Hologen AI, including a $200 million cash upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson's disease - RMAT designation includes the bene
The global cone rod dystrophy market, valued at US$131.29 million in 2024, is projected to reach US$177.59 million by 2030, growing at a CAGR of 5.33%. Key drivers include advancements in gene therapi
MeiraGTx Holdings: Gaining Regulatory Focus
10:50am, Tuesday, 25'th Mar 2025
MeiraGTx (MGTX) develops gene therapies for ocular diseases, Parkinson's Disease, and xerostomia, with multiple assets in advanced clinical stages showing promising efficacy and safety data. MGTX uses
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars
09:51am, Thursday, 13'th Mar 2025
On Thursday, MeiraGTx Holdings plc MGTX announced a broad strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models of real-world clinical data for clini
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
08:00am, Thursday, 13'th Mar 2025
- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 millio
- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen
LONDON and NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the publication of re
MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value
04:09pm, Wednesday, 22'nd Jan 2025
MeiraGTx Holdings plc is advancing AAV-AIPL1 for AIPL1-associated Leber congenital amaurosis 4, with a near-term BLA filing in the UK under Exceptional Circumstance possible. Bota-vec, developed with
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company's proprietary tec
MeiraGTx Holdings: Behind The Recent Rally
02:18pm, Tuesday, 03'rd Dec 2024
MeiraGTx Holdings plc has rallied over 40% following promising Parkinson's disease data, with significant potential in its Riboswitch platform for gene expression control. The company's diverse pipeli
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates
10:15am, Wednesday, 13'th Nov 2024
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.74 per share a year ago.
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
11:20am, Wednesday, 16'th Oct 2024
MeiraGTx stock rises 15% as gene therapy candidate betters sham treatment in Parkinson's disease patients.
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
07:46am, Wednesday, 16'th Oct 2024
MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
01:32pm, Tuesday, 15'th Oct 2024
MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores. The company plans to discuss phase
